medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2015, Número 10

<< Anterior Siguiente >>

Ginecol Obstet Mex 2015; 83 (10)


Proteómica y síndrome de ovario poliquístico: ¿encontraremos aquí el eslabón perdido? Revisión de la bibliografía

Carmona-Ruiz IO, Saucedo LE, Moraga-Sánchez MR, Hernáez-Sánchez ML, Gutiérrez-Blázquez MD, Romeu-Sarrió A

Idioma: Español
Referencias bibliográficas: 84
Paginas: 614-626
Archivo PDF: 470.86 Kb.


RESUMEN

El síndrome de ovario poliquístico es la enfermedad ginecológica y endocrina más frecuente en mujeres en edad reproductiva. Es, además, una de las causas más comunes de hiperandrogenismo y anovulación que incrementan el riesgo de síndrome metabólico, diabetes mellitus tipo 2 y enfermedad cardiovascular. A la fecha, su causa es incierta. Se dice que puede ser resultado de la interacción de variantes genéticas con factores ambientales que dependen ampliamente de la etnicidad. La proteómica permite estudiar la expresión de cientos o miles de proteínas para conocer el estado fisiológico de un tejido u órgano a nivel molecular e identificar biomarcadores específicos de enfermedad. Su aplicación en el síndrome de ovario poliquístico permite identificar las proteínas que participan en la patogénesis del síndrome y desarrollar técnicas diagnósticas precisas y enfoques específicos de tratamiento.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health carerelated economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab 2005;90(8):4650-8.

  2. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999;84(6):1897-9.

  3. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91(1):2-6.

  4. Essah PA, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;29(3):270- 80.

  5. Amsterdam EA-SrPCWG. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS). Human Reproduction. 2012;27(1):14-24.

  6. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9):3078-82.

  7. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(7):2434-8.

  8. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745-9.

  9. Lauritsen MP, Bentzen JG, Pinborg A, Loft A, Forman JL, Thuesen LL, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Human Reproduction. 2014.

  10. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clinical endocrinology. 1999;51(6):779-86.

  11. Insenser M, Montes-Nieto R, Murri M, Escobar-Morreale HF. Proteomic and metabolomic approaches to the study of polycystic ovary syndrome. Molecular and cellular endocrinology. 2013;370(1-2):65-77.

  12. Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Seminars in reproductive endocrinology. 1997;15(2):111-22.

  13. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin sensitizers for polycystic ovary syndrome. Clinical obstetrics and gynecology. 2003;46(2):325-40.

  14. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril. 2004;81(1):114-9.

  15. Ciampelli M, Fulghesu AM, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism: clinical and experimental. 1999;48(2):167-72.

  16. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecologial endocrinology the official journal of the international Society og Gynecological Endocronology. 2012;28(7):509-15.

  17. Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2006;86 Suppl 1:S13-4.

  18. Pasquali R, Pelusi C, Ragazzini C, Hasanaj R, Gambineri A. Glucose tolerance, insulin secretion and insulin sensitivity in polycystic ovary syndrome. Journal of the pancreas. 2002;3(1):1-7.

  19. Xita N, Tsatsoulis A. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. Clin Endocrinol Metab. 2006;91(5):1660-6.

  20. Dumesic DA, Richards JS. Ontogeny of the ovary in polycystic ovary syndrome. Fertil Steril. 2013;100(1):23-38.

  21. Franks S, Berga SL. Does PCOS have developmental origins? Fertil Steril. 2012;97(1):2-6.

  22. Welt CK, Carmina E. Clinical review: Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. Clin Endocrinol Metab. 2013;98(12):4629-38.

  23. de Zegher F, Lopez-Bermejo A, Ibanez L. Adipose tissue expandability and the early origins of PCOS. Trends in endocrinology and metabolism: TEM. 2009;20(9):418-23.

  24. Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends in endocrinology and metabolism: TEM. 2007;18(7):266-72.

  25. Zawadski J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. Towards a rational approach. In: Dunaif A, Givens J, Haseltine F, Merriam G, editors. Polycystic ovary syndrome Current issues in Endocrinology and Metabolism. 4. Boston: Blackwell Scientific; 1992. p. 377 - 84.

  26. Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004;19:41 - 7.

  27. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W, et al. Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237 - 45.

  28. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. Clin Endocrinol Metab. 2006;91(11):4237-45.

  29. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG: an International Journal of Obstetrics and Gynaecology. 2006;113(10):1210-7.

  30. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Human reproduction. 2012;27(10):3067-73.

  31. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome December 3–5, 20122012 01/03/2014. Available from: http://prevention.nih.gov/workshops/2012/ pcos/docs/PCOS_Final_Statement.pdf.

  32. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Franks S, Gambineri A, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. European journal of endocrinology / European Federation of Endocrine Societies. 2014;171(4):P1-29.

  33. Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2007;23(3):146-52.

  34. Pasquali R, Gambineri A. Insulin-sensitizing agents in polycystic ovary syndrome. European journal of endocrinology / European Federation of Endocrine Societies. 2006;154(6):763-75.

  35. Atiomo WU, Khalid S, Ziauddin A, Tooth D, Layfield R. Framework for a systems approach to proteomic biomarker profiling in polycystic ovary syndrome. Expert review of proteomics. 2009;6(5):469-99.

  36. Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? Annals of the New York Academy of Sciences. 2010;1212:59-77.

  37. Kosova G, Scott NM, Niederberger C, Prins GS, Ober C. Genome-wide association study identifies candidate genes for male fertility traits in humans. American journal of human genetics. 2012;90(6):950-61.

  38. Swarr DT, Hakonarson H. Unraveling the complex genetic underpinnings of asthma and allergic disorders. Current opinion in allergy and clinical immunology. 2010;10(5):434-42.

  39. Van Winkel R, Esquivel G, Kenis G, Wichers M, Collip D, Peerbooms O, et al. REVIEW: Genome-wide findings in schizophrenia and the role of gene-environment interplay. CNS neuroscience & therapeutics. 2010;16(5):e185-92.

  40. McCarthy MI. Genomics, type 2 diabetes, and obesity. The New England journal of medicine. 2010;363(24):2339-50.

  41. Kosova G, Urbanek M. Genetics of the polycystic ovary syndrome. Molecular and cellular endocrinology. 2013;373(1- 2):29-38.

  42. Ma X, Fan L, Meng Y, Hou Z, Mao YD, Wang W, et al. Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Molecular human reproduction. 2007;13(8):527-35.

  43. Insenser M, Escobar-Morreale HF. Application of proteomics to the study of polycystic ovary syndrome. Journal of endocrinological investigation. 2011;34(11):869-75.

  44. Gupta S, Ghulmiyyah J, Sharma R, Halabi J, Agarwal A. Power of proteomics in linking oxidative stress and female infertility. BioMed research international. 2014;2014:916212.

  45. Wei Q, Galbenus R, Raza A, Cerny RL, Simpson MA. Androgen- stimulated UDP-glucose dehydrogenase expression limits prostate androgen availability without impacting hyaluronan levels. Cancer research. 2009;69(6):2332-9.

  46. Escobar-Morreale HF. Iron metabolism and the polycystic ovary syndrome. Trends in endocrinology and metabolism: TEM. 2012;23(10):509-15.

  47. Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clinical endocrinology. 1994;41(4):463-71.

  48. Legro RS, Blanche P, Krauss RM, Lobo RA. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome: influence of insulin and genetic factors. Fertil Steril. 1999;72(6):990-5.

  49. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. Clin Endocrinol Metab. 2008;93(2):470-6.

  50. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. Clin Endocrinol Metab. 2010;95(5):2038-49.

  51. Sun L, Hu W, Liu Q, Hao Q, Sun B, Zhang Q, et al. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res. 2012;11(5):2937-46.

  52. Brewer HB, Jr. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. The American journal of cardiology. 1999;83(9B):3F-12F.

  53. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. European journal of biochemistry / FEBS. 1997;244(1):1-14.

  54. Corton M, Botella-Carretero JI, Lopez JA, Camafeita E, San Millan JL, Escobar-Morreale HF, et al. Proteomic analysis of human omental adipose tissue in the polycystic ovary syndrome using two-dimensional difference gel electrophoresis and mass spectrometry. Human reproduction. 2008;23(3):651-61.

  55. Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Human reproduction update. 2013;19(3):268-88.

  56. Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Human reproduction. 2003;18(4):721-7.

  57. Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity? Clinical endocrinology. 2004;60(5):560-7.

  58. Choi DH, Lee WS, Won M, Park M, Park HO, Kim E, et al. The apolipoprotein A-I level is downregulated in the granulosa cells of patients with polycystic ovary syndrome and affects steroidogenesis. Journal of proteome research. 2010;9(9):4329-36.

  59. Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse C, et al. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. The Journal of biological chemistry. 1999;274(27):18947-56.

  60. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocrine reviews. 2005;26(2):251-82.

  61. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. The New England journal of medicine. 1999;340(6):448-54.

  62. Insenser M, Martinez-Garcia MA, Montes R, San-Millan JL, Escobar-Morreale HF. Proteomic analysis of plasma in the polycystic ovary syndrome identifies novel markers involved in iron metabolism, acute-phase response, and inflammation. Clin Endocrinol Metab. 2010;95(8):3863-70.

  63. Kawano Y, Narahara H, Miyamura K, Mifune K, Miyakawa I. Inhibitory effect of transferrin on progesterone production in the granulosa cell of humans in vivo and porcine granulosa cell in vitro. Gynecologic and obstetric investigation. 1995;40(1):1-4.

  64. Gonzalez F, Kirwan JP, Rote NS, Minium J. Elevated circulating levels of tissue factor in polycystic ovary syndrome. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2013;19(1):66-72.

  65. Lindholm A, Bixo M, Eliasson M, Hudecova M, Arnadottir R, Holte J, et al. Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology. 2010;26(10):743-8.

  66. Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. Clin Endocrinol Metab. 2002;87(8):3871-5.

  67. Manneras-Holm L, Baghaei F, Holm G, Janson PO, Ohlsson C, Lonn M, et al. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. Clin Endocrinol Metab. 2011;96(4):1068-76.

  68. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes. 2003;52(1):1-8.

  69. Gonzalez F, Nair KS, Daniels JK, Basal E, Schimke JM, Blair HE. Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. Clin Endocrinol Metab. 2012;97(8):2836-43.

  70. Ott J, Wattar L, Kurz C, Seemann R, Huber JC, Mayerhofer K, et al. Parameters for calcium metabolism in women with polycystic ovary syndrome who undergo clomiphene citrate stimulation: a prospective cohort study. European journal of endocrinology / European Federation of Endocrine Societies. 2012;166(5):897-902.

  71. Ranjzad F, Mahban A, Shemirani AI, Mahmoudi T, Vahedi M, Nikzamir A, et al. Influence of gene variants related to calcium homeostasis on biochemical parameters of women with polycystic ovary syndrome. Journal of assisted reproduction and genetics. 2011;28(3):225-32.

  72. Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids. 1999;64(6):430-5.

  73. Monastyrskaya K, Babiychuk EB, Draeger A. The annexins: spatial and temporal coordination of signaling events during cellular stress. Cellular and molecular life sciences: CMLS. 2009;66(16):2623-42.

  74. Shi Y, Zhao H, Shi Y, Cao Y, Yang D, Li Z, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nature genetics. 2012;44(9):1020-5.

  75. Wang S, Alvero R. Racial and ethnic differences in physiology and clinical symptoms of polycystic ovary syndrome. Seminars in reproductive medicine. 2013;31(5):365-9.

  76. Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM, et al. Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study. Fertil Steril. 2011;96(1):224-9 e2.

  77. Legro RS, Myers ER, Barnhart HX, Carson SA, Diamond MP, Carr BR, et al. The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril. 2006;86(4):914-33.

  78. Hillman JK, Johnson LN, Limaye M, Feldman RA, Sammel M, Dokras A. Black women with polycystic ovary syndrome (PCOS) have increased risk for metabolic syndrome and cardiovascular disease compared with white women with PCOS [corrected]. Fertil Steril. 2014;101(2):530-5.

  79. Dilbaz B, Cinar M, Ozkaya E, Tonyali NV, Dilbaz S. Health related quality of life among different PCOS phenotypes of infertile women. Journal of the Turkish German Gynecological Association. 2012;13(4):247-52.

  80. Jones H, Sprung VS, Pugh CJ, Daousi C, Irwin A, Aziz N, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. Clin Endocrinol Metab. 2012;97(10):3709-16.

  81. Kar S. Anthropometric, clinical, and metabolic comparisons of the four Rotterdam PCOS phenotypes: A prospective study of PCOS women. Journal of human reproductive sciences. 2013;6(3):194-200.

  82. Palomba S, Falbo A, Chiossi G, Tolino A, Tucci L, La Sala GB, et al. Early trophoblast invasion and placentation in women with different PCOS phenotypes. Reproductive biomedicine online. 2014;29(3):370-81.

  83. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril. 2007;88(5):1389-95.

  84. Vaggopoulos V, Trakakis E, Chrelias C, Panagopoulos P, Basios G, Makridima S, et al. Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with insulin resistance. J Endocrinol Invest. 2013;36(7):478-84.




2020     |     www.medigraphic.com